Daniel O'Mahony

Seroba Life Sciences thesis

The Millipede88® is the first 088 aspiration catheter with patented corrugated technology cleared for standalone direct aspiration – no large-bore intermediary required- backed by independently adjudicated MARRS study data showing a 77% first-pass effect1 in M1 occlusions and 96% delivery success. Perfuze, a medical device company dedicated to advancing stroke treatment through next-generation catheter technology, today announced it has received … Medtech Explore Europe is a science powerhouse, but can it also lead in biotech and healthcare innovation? That’s the pressing question at the heart

Sector and stage focus

• Series B: BioTech, Medical Devices, Pharmaceuticals
• Series A: Medical Devices, Pharmaceuticals, BioTech

Is Daniel O'Mahony a fit for your round?

Upload your pitch deck and see whether Daniel O'Mahony appears in your top 20 matches.